AR094275A1 - COMPOSICION INMUNOGENICA QUE COMPRENDE LA PROTEINA CDTb DE CLOSTRIDIUM DIFFICILE - Google Patents
COMPOSICION INMUNOGENICA QUE COMPRENDE LA PROTEINA CDTb DE CLOSTRIDIUM DIFFICILEInfo
- Publication number
- AR094275A1 AR094275A1 ARP130105022A ARP130105022A AR094275A1 AR 094275 A1 AR094275 A1 AR 094275A1 AR P130105022 A ARP130105022 A AR P130105022A AR P130105022 A ARP130105022 A AR P130105022A AR 094275 A1 AR094275 A1 AR 094275A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- protein
- clostridium difficile
- isolated
- cdtb
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente se refiere a composiciones inmunogénicas que comprenden una proteína CDTa y una proteína CDTb de Clostridium difficile aislada. En particular, la proteína CDTb de Clostridium difficile aislada es, idóneamente, una proteína CDTb truncada que comprende el dominio de unión al receptor o una proteína CDTb murada que no se puede unir a CDTa y la proteína CDTa de Clostridium difficile aislada es idóneamente una proteína CDTa truncada que no comprende el domino en C-terminal. En particular, la presente también se refiere a proteínas de fusión que comprenden una proteína CDTa y una proteína CDTb y, también, proteínas de fusión entre una proteína toxina A aislada de Clostridium difficile y/o una proteína toxina B aislada de Clostridium difficile fusionadas a una proteína CDTb. La presente se refiere además a composiciones que comprenden fragmentos o variantes de SEC ID Nº 3, SEC ID Nº 7, SEC ID Nº 16, SEC ID Nº 9, SEC ID Nº 51, SEC ID Nº 34, SEC ID Nº 36, SEC ID Nº 50, SEC ID Nº 14, SEC ID Nº 15, SEC ID Nº 46, SEC ID Nº 48, SEC ID Nº 52, SEC ID Nº 54, SEC ID Nº 40, SEC ID Nº 41 o SEC ID Nº 42 o SEC ID Nº 43 o SEC ID Nº 44 o SEC ID Nº 45. Reivindicación 1: Una composición inmunogénica que comprende la proteína CDTb de Clostridium difficile en la que la composición no comprende adicionalmente una proteína aislada que tiene una similitud de al menos 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% ó 100% con la SEC ID Nº 1, la SEC ID Nº 31 o la SEC ID Nº 32.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1223342.5A GB201223342D0 (en) | 2012-12-23 | 2012-12-23 | Immunogenic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR094275A1 true AR094275A1 (es) | 2015-07-22 |
Family
ID=47682553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130105022A AR094275A1 (es) | 2012-12-23 | 2013-12-20 | COMPOSICION INMUNOGENICA QUE COMPRENDE LA PROTEINA CDTb DE CLOSTRIDIUM DIFFICILE |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9669083B2 (es) |
| EP (1) | EP2934579B1 (es) |
| JP (1) | JP6515036B2 (es) |
| CN (1) | CN105120892B (es) |
| AR (1) | AR094275A1 (es) |
| AU (1) | AU2013366450A1 (es) |
| BR (1) | BR112015014727B8 (es) |
| CA (1) | CA2894951C (es) |
| ES (1) | ES2748054T3 (es) |
| GB (1) | GB201223342D0 (es) |
| SG (1) | SG11201504701UA (es) |
| WO (1) | WO2014096393A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6121421B2 (ja) | 2010-09-03 | 2017-04-26 | バルネバ オーストリア ジーエムビーエイチ | Ｃ．ディフィシルの毒素ａおよび毒素ｂタンパク質の単離ポリペプチドならびにその使用 |
| SI2699587T1 (sl) | 2011-04-22 | 2019-08-30 | Wyeth Llc | Sestavek, povezan z mutantskim clostridium difficile toksinom, in metode omenjenega sestavka |
| RU2014127714A (ru) * | 2011-12-08 | 2016-01-27 | Новартис Аг | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile |
| BR122016023101B1 (pt) * | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| EP3636278A3 (en) * | 2014-06-25 | 2020-07-15 | GlaxoSmithKline Biologicals S.A. | Clostridium difficile immunogenic composition |
| WO2018170238A2 (en) | 2017-03-15 | 2018-09-20 | Novavax, Inc. | Methods and compositions for inducing immune responses against clostridium difficile |
| US10933126B2 (en) | 2018-05-03 | 2021-03-02 | The Board Of Regents Of The University Of Oklahoma | Clostridium difficile immunogenic compositions and methods of use |
| CA3102353A1 (en) | 2018-06-19 | 2019-12-26 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| CN111793130B (zh) * | 2019-03-20 | 2021-09-14 | 华中农业大学 | 一株副猪嗜血杆菌CdtB杂交瘤细胞及单克隆抗体应用 |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2396652T3 (da) * | 2009-02-11 | 2018-01-29 | Cedars Sinai Medical Center | Diagnose af inflammatorisk tarmsyndrom baseret på cytoletalt udspilende toksin |
| US10046040B2 (en) * | 2009-11-16 | 2018-08-14 | University Of Maryland, Baltimore | Multivalent live vector vaccine against Clostridium difficile-associated disease |
| JP6121421B2 (ja) * | 2010-09-03 | 2017-04-26 | バルネバ オーストリア ジーエムビーエイチ | Ｃ．ディフィシルの毒素ａおよび毒素ｂタンパク質の単離ポリペプチドならびにその使用 |
| AR089797A1 (es) | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
-
2012
- 2012-12-23 GB GBGB1223342.5A patent/GB201223342D0/en not_active Ceased
-
2013
- 2013-12-20 EP EP13817931.2A patent/EP2934579B1/en active Active
- 2013-12-20 US US14/653,989 patent/US9669083B2/en active Active
- 2013-12-20 BR BR112015014727A patent/BR112015014727B8/pt active Search and Examination
- 2013-12-20 CN CN201380073503.5A patent/CN105120892B/zh active Active
- 2013-12-20 ES ES13817931T patent/ES2748054T3/es active Active
- 2013-12-20 AR ARP130105022A patent/AR094275A1/es unknown
- 2013-12-20 JP JP2015548649A patent/JP6515036B2/ja active Active
- 2013-12-20 SG SG11201504701UA patent/SG11201504701UA/en unknown
- 2013-12-20 CA CA2894951A patent/CA2894951C/en active Active
- 2013-12-20 AU AU2013366450A patent/AU2013366450A1/en not_active Abandoned
- 2013-12-20 WO PCT/EP2013/077762 patent/WO2014096393A1/en active Application Filing
-
2017
- 2017-05-15 US US15/595,651 patent/US20180043005A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015014727B8 (pt) | 2022-09-20 |
| BR112015014727B1 (pt) | 2022-08-02 |
| BR112015014727A2 (pt) | 2017-10-10 |
| CN105120892A (zh) | 2015-12-02 |
| EP2934579A1 (en) | 2015-10-28 |
| GB201223342D0 (en) | 2013-02-06 |
| CN105120892B (zh) | 2020-07-31 |
| JP6515036B2 (ja) | 2019-05-15 |
| WO2014096393A1 (en) | 2014-06-26 |
| US20150313985A1 (en) | 2015-11-05 |
| US9669083B2 (en) | 2017-06-06 |
| EP2934579B1 (en) | 2019-08-07 |
| CA2894951C (en) | 2023-05-09 |
| ES2748054T3 (es) | 2020-03-12 |
| CA2894951A1 (en) | 2014-06-26 |
| US20180043005A1 (en) | 2018-02-15 |
| AU2013366450A1 (en) | 2015-07-23 |
| SG11201504701UA (en) | 2015-07-30 |
| JP2016504993A (ja) | 2016-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR094275A1 (es) | COMPOSICION INMUNOGENICA QUE COMPRENDE LA PROTEINA CDTb DE CLOSTRIDIUM DIFFICILE | |
| CY1119916T1 (el) | Ανοσογονικη συνθεση | |
| AR091069A1 (es) | Proteinas de union a antigeno dirigidas contra el receptor st2 | |
| PE20191551A1 (es) | Polipeptidos de union al receptor de transferrina disenados | |
| PE20120532A1 (es) | ANTICUERPOS ANTI-ActRIIB | |
| MX2021006017A (es) | Polipeptidos de folistatina y sus usos. | |
| MX2012003058A (es) | Vacunas dirigidas a celulas de langerhans. | |
| BR112019023071A2 (pt) | proteínas de fusão do receptor tgf-beta do tipo ii e uso das mesmas | |
| MX351502B (es) | Anticuerpos de union de albumina y fragmentos de union de los mismos. | |
| PE20142451A1 (es) | Composiciones de conjugados de xten y metodos para realizar las mismas | |
| WO2013184938A3 (en) | Fusion polypeptides comprising mucin-domain polypeptide linkers | |
| MX361076B (es) | Proteínas multifunción que comprenden complejo mayor de histocompatibilidad (cmh) de clase i multivalente unido mediante disulfuro. | |
| BR112018012694A2 (pt) | composição de célula dendrítica, vacina de célula dendrítica, composição e kit | |
| MX2021000030A (es) | Metodos y composiciones que utilizan polipeptidos variantes klotho. | |
| UA107330C2 (uk) | Туберкульозний білок rv3616c та його застосування | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
| EA201491277A1 (ru) | Противораковый слитый белок | |
| PE20160528A1 (es) | Anticuerpos | |
| IN2014DN08325A (es) | ||
| MX2015000754A (es) | Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos. | |
| MX2018013778A (es) | Mutante cd200 y sus usos. | |
| MY191217A (en) | Group a streptococcus vaccine | |
| CL2011002994A1 (es) | Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal. | |
| NZ702285A (en) | Staphylococcal coagulase antigens and methods of their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |